Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.51 USD
Change Today 0.00 / 0.00%
Volume 240.6K
AVEO On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (AVEO) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - $3.50
52 Week Low
12/9/14 - $0.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

aveo pharmaceuticals inc (AVEO) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (AVEO) Details

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. The company’s development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

57 Employees
Last Reported Date: 03/6/15
Founded in 2001

aveo pharmaceuticals inc (AVEO) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $504.1K
Executive Officer
Total Annual Compensation: $480.3K
Compensation as of Fiscal Year 2014.

aveo pharmaceuticals inc (AVEO) Key Developments

AVEO Pharmaceuticals, Inc. Approves Amendment to the Restated Certificate of Incorporation

AVEO Pharmaceuticals, Inc. announced at the AGM held on May 28, 2015, it has approved amendment to the company's restated certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.

AVEO Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:00 AM

AVEO Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

AVEO Oncology Announces New Corporate Headquarters in Cambridge, Massachusetts

AVEO Oncology announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective on May 26, 2015. The new facility consists of approximately 5,000 square feet of office space under flexible lease terms, with no laboratory or vivarium space. The new headquarters represents a reduction of approximately 90% in facilities from its prior Cambridge location at 650 E. Kendall Square.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVEO:US $1.51 USD 0.00

AVEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.71 USD -0.05
Bristol-Myers Squibb Co $64.66 USD +0.36
Exelixis Inc $5.41 USD -0.03
GlaxoSmithKline SAE £11.50 EGP 0.00
Takeda Pharmaceutical Co Ltd ¥6,083 JPY +15.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AVEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.8x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at